1. Home
  2. SCD vs LXEO Comparison

SCD vs LXEO Comparison

Compare SCD & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LMP Capital and Income Fund Inc.

SCD

LMP Capital and Income Fund Inc.

HOLD

Current Price

$15.46

Market Cap

359.2M

Sector

Finance

ML Signal

HOLD

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

HOLD

Current Price

$4.67

Market Cap

396.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCD
LXEO
Founded
2003
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
359.2M
396.5M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
SCD
LXEO
Price
$15.46
$4.67
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$18.44
AVG Volume (30 Days)
94.2K
1.0M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
9.63%
N/A
EPS Growth
N/A
39.81
EPS
N/A
N/A
Revenue
N/A
$654,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.79
$3.91
52 Week High
$16.18
$10.99

Technical Indicators

Market Signals
Indicator
SCD
LXEO
Relative Strength Index (RSI) 49.03 47.48
Support Level $15.13 $4.30
Resistance Level $15.48 $5.36
Average True Range (ATR) 0.18 0.35
MACD -0.01 0.01
Stochastic Oscillator 52.83 26.02

Price Performance

Historical Comparison
SCD
LXEO

About SCD LMP Capital and Income Fund Inc.

Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Share on Social Networks: